Overview

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.

Phase:

Phase 3

Details

Lead Sponsor:

JW Pharmaceutical

Treatments:

Anagliptin
Metformin
Sitagliptin Phosphate